Ventricular Myocyte Differentiation via Smad1/5/8 and Wnt Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for differentiating pluripotent stem cells into ventricular myocytes (VMs) are inefficient and result in heterogeneous populations, lacking the ability to produce highly homogeneous VMs necessary for cell transplantation therapy and cardiac-toxicological analysis.
Innovation Solution
Activation of the Smad1/5/8 signaling pathway through bone morphogenetic proteins (BMP2/4) and inhibition of the Wnt signaling pathway using DKK1/IWP/IWR, combined with retinoic acid regulation, to direct the differentiation of pluripotent stem cells into VMs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional differentiation methods (embryoid body formation or direct monolayer differentiation) are used, then cardiomyocytes can be generated, but the differentiation efficiency is low and the cell population is heterogeneous
Solution Approach 1:
The patent applies parameter changes by systematically optimizing the concentrations and timing of multiple signaling molecules (BMP4 at 100 ng/mL, DKK1 at 100 ng/mL, IWP-1 at 10 μM, IWR-1 at 10 μM) throughout the differentiation process. This precise parameter control transforms the differentiation outcome from heterogeneous to highly homogeneous ventricular myocytes while maintaining high efficiency
Solution Approach 2:
The patent uses intermediary substances including BMP4 to activate Smad1/5/8 signaling, DKK1 and IWP-1/IWR-1 to inhibit Wnt signaling, and retinoic acid to modulate RAR pathways. These intermediaries mediate the differentiation process to achieve ventricular myocyte specification with high homogeneity and efficiency
2Manufacturing precision
If purification steps are implemented to achieve high purity VMs, then cell subtype purity improves, but the process complexity and time increase
Solution Approach 1:
The patent extracts and removes the need for purification steps by achieving high purity ventricular myocytes directly through optimized differentiation conditions. The method eliminates the requirement for additional separation or purification procedures by preventing non-ventricular cell formation through precise signaling pathway control
Solution Approach 2:
The differentiation system performs self-service by automatically generating highly pure ventricular myocytes through the optimized combination of signaling molecules. The system self-regulates to produce the desired cell type without requiring external intervention for purification or selection
Data Source
Figure 1A~1C
Figure 2A~3
Figure 4A~4B
AI summary
Provided in the present invention is a method for inducing pluripotent stem cells to differentiate into ventricular myo-cytes in vitro, which is achieved by maintaining, amplifying and culturing pluripotent stem cells in vitro, adding a substance capable of activating the Smadl/5/8 signaling pathway directly or indirectly into the culture medium when pluripotent stem cells are in the middle stage of myocardial differentiation, i.e. the period of differentiating into cardiac muscle cells from mesoderm cells or myocardial precursor cells, which enables stem cells to differentiate into ventricular myocytes directionally. Ventricular myocytes with biological activity and function are obtained successfully by means of the method of the present invention, which reveals the regulatory mechanism during differentiation of myocardial precursor cells into ventricular myocytes; moreover, the human ventricular myo-cytes obtained via differentiation can be widely used in treating myocardial infarction by cell transplantation, in toxicological analys - is of the heart and in the development of heart-related drugs.